Abstract: An enteral nutritional product containing either bovine .kappa.-casein or human .kappa.-casein at a concentration greater than that found in human or bovine milk and sufficient to inhibit infection of mammalian cells by human rotavirus.

Abstract: The present invention provides a new fat mixture for infant and adult nutrition which possesses adequate levels and ratios of polyunsaturated fats and long chain polyunsaturated fats. These fat mixtures possess adequate levels of phospholipids and an adequate relationship between oleic acid, linoleic acid and .alpha.-linolenic acid as well as adequate levels of long chain polyunsaturated fatty acids of both the n6 and n3 series. In addition, the fat mixtures of the present invention possess an adequate ratio of arachidonic acid (20:4n6) to docosahexaenoic acid (22:6n3). These fat mixtures are modeled on the fat content of human milk for infant diets and on the mediterranean diet for adult nutritional products. Diets containing these mixtures promote the growth and development of the infant and contribute to the prevention and treatment of some diseases in adults.

Abstract: An improved enteral formula containing ribo-nucleotide equivalents (RNA, mono-, di- and triphosphate nucleotides, nucleosides and adducts such as activated sugars) at a level of at least 10 mg/100 Kcal (kilocalorie) of formula. More specifically, an infant formula containing at least 10 milligrams of nucleotide equivalents per 100 Kcal of formula where the nucleotide equivalents consist of RNA; mono-, di-, and triphosphate esters of adenosine, cytidine, guanosine, and uridine, and the d-ribose adducts thereof; and wherein the weight ratio of said cytidine nucleotide equivalents to said uridine nucleotide equivalents is 1.5:1 to 2.6:1; of said cytidine nucleotide equivalent to said adenosine nucleotide equivalents is 2:1 to 3.9:1; and of said cytidine nucleotide equivalents to said guanosine nucleotide equivalents is 1.75:1 to 2.8:1, is disclosed. The formula comprises carbohydrates, lipids, proteins, vitamins and minerals and four (4) ribo-nucleotide equivalents at specific levels and ratios.

Abstract: The present invention is a liquid nutritional product with improved physical stability comprising: (a) a liquid nutritional mixture containing fat at a concentration sufficient to have the liquid nutritional mixture be susceptible to creaming and containing suspended minerals present at a concentration sufficient to have the liquid nutritional mixture be susceptible to sedimentation; (b) a carrageenan/microcrystalline cellulose/carboxymethyl cellulose additive composition comprising: (i) iota-carrageenan present in an amount of about 100-800 ppm of the liquid nutritional product; (ii) a mixture of microcrystalline cellulose/carboxymethyl cellulose, the mixture present in an amount of from about 600-3000 ppm of the liquid nutritional product. In a preferred embodiment, microcrystalline cellulose is present in a range of from about 1000 ppm to about 2500 ppm, while the iota-carrageenan is present in a range of from about 100 ppm to about 300.

Abstract: A liquid enteral nutritional product has been formulated which has utility, for example, for persons with cancer who are not currently undergoing radiation therapy and/or chemotherapy. The nutritional product is characterized by a fatty acid profile wherein, by weight: (a) the ratio of the sum of the n-3 to n-6 fatty acids is in the range of 1.37 to 1.70; (b) Eicosapentaenoic Acid (23:6n-3) is about 2.7-3.0% of total fatty acids.; and (c) Docosahexaenoic Acid (22:6n-3) is about 1.3-1.4% of total fatty acids. Preferably the nutritional product also contains intact protein, .beta.-carotene, carnitine and taurine.

Abstract: A calcium supplement in solid form contains calcium glycerophosphate, vitamin D and vitamin C.

Abstract: A method of making a stable liquid nutritional product is disclosed. The method includes the steps of forming a protein solution, a carbohydrate solution, and an oil blend, adding a small amount of a nutritional ingredient containing soy polysaccharide as a source of dietary fiber to one of these, combining appropriate quantities of these solutions, and heat processing and microfluidizing the combined solution. The amount of the nutritional ingredient containing soy polysaccharide as a source of dietary fiber is preferably less than 6,500 ppm, and is most preferably between 3,000 and 6,000 ppm of the final product.

Abstract: A solid composition for generating gases when ignited is a combination 5-aminotetrazole and at least two oxidizers selected from the group consisting of potassium nitrate, potassium per-chlorate, ferric oxide, copper oxide and manganese dioxide.

Abstract: Process for the preparation of ground cereal based foods and food products obtained thereby. The process comprises an initial phase of toasting all the cereals used and a hydrolyzation phase with amylolytic enzymes of the toasted cereals. The food products obtained have better organoleptic and hygienic properties, improved dispersibility, and allow reduction in the amount of edulcorants to be added.

Abstract: This invention discloses that certain fragments of a pulmonary surfactant protein exhibit unexpected surface activity. These protein fragments are useful in preparing formulations for the treatment of respiratory distress syndrome.

Abstract: An enteral nutritional product has been formulated for persons who are currently undergoing radiation therapy and/or chemotherapy. The nutritional product has a protein system which includes a soy protein hydrolysate. The nutritional product is very low in folic acid, contains .beta.-carotene, and has a ratio of n-6 to n-3 fatty acids that is in the range of about 1.3:1 to 2.5:1.

Abstract: A therapeutic method is provided to reduce ischemia/reperfusion injury to the heart muscle by perfusing pyruvylglycine into the circulatory system of a patient who has had a heart attack or suffered coronary occlusion.

Abstract: An improved enteral nutritional formula containing ribo-nucleotide equivalents (RNA, mono-, di- and triphosphate nucleotides, nucleosides and adjuncts such as activated sugars) at a level of at least 10 mg/100 Kcal (kilocalorie) of formula is disclosed. The formula comprises carbohydrates, lipids, proteins, vitamins and minerals and four (4) ribo-nucleotide equivalents at specific levels and ratios. The invention also discloses novel methods of production and analytical techniques. An infant formula containing cytidine nucleotide equivalents in the range of 29 to 39 mg/liter of formula, uridine nucleotide equivalents in the range of 15 to 20 mg/liter of formula, adenosine nucleotide equivalents in the range of 10 to 15 mg/liter of formula and guanosine nucleotide equivalents in the range of 14 to 20 mg/liter of formula provides a dietary formula that enhances the immune system and alleviates diarrhea.

Abstract: An improved enteral nutritional formula containing ribo-nucleotide equivalents (RNA, mono-, di- and triphosphate nucleotides, nucleosides and adjuncts such as activated sugars) at a level of at least 10 mg/100 Kcal (kilocalorie) of formula is disclosed. The formula comprises carbohydrates, lipids, proteins, vitamins and minerals and four (4) ribo-nucleotide equivalents at specific levels and ratios. The invention also discloses novel methods of production and analytical techniques. This invention also provides a dietary formula that enhances the immune system and alleviates diarrhea.

Abstract: A method is disclosed for improving the stability of Vitamin D in liquid nutritional products which contain hydrolyzed protein or free amino acids as nitrogen sources. Vitamin C is added before or after a preliminary heat treatment of the liquid nutritional product and at a concentration exceeding 300 mg/l, such that the initial concentration of Vitamin C is at least 300 mg/l during the shelf-life of the liquid nutritional product. An emulsifier is added to the liquid nutritional product prior to preliminary heat treatment, the emulsifier being a diacetyltartaric acid ester of monoglycerides and diglycerides. Cystine is added following the preliminary heat treatment.

Abstract: A method of improving the nutritional status and reversing the characteristic diarrhea and inflammatory condition in a mammalian creature having ulcerative colitis or inflammation of the colon which contains in combination (a) an oil blend which contains eicosapentaenoic acid (20:5n3) and/or docosahexaenoic acid (22:6n3), and (b) a source of indigestible carbohydrate which is metabolized to short chain fatty acids by microorganisms present in the human colon. Preferably the nutritional product also contains one or more nutrients which act as antioxidants.

Abstract: A skin lotion containing a linear polydimethylsiloxane polymer, a non-ionic emulsifier, consisting of polyoxyethylene sorbitan fatty acid esters, sorbitan fatty acid esters, polyoxyethylene alcohols, or polyoxyethylene fatty ethers aloe vera, an alkoxylated ether/ester, sodium citrate, citric acid, a blend of propylene glycol, diazolidinyl urea, methyl paraben and propyl paraben, and water. Most preferably the buffering system results in the lotion having a pH of about 5.2 which neutralizes acidic and basic by-products of urine and fecal matter. The lotion has a preferred viscosity in the range of 10-20,000 centipoise. The lotion is easily washed off with soap and water and is useful in the protection and treatment of diaper rash.

Abstract: The one-way cross-slit valve of the invention is made of an elastomeric material and has a hollow cylindrical body with first and second ends and an axis and a passageway through the body, the passageway being entirely intercepted by a ridge and valley wall or web structure integrally joined to the cylindrical body. There are just two ridges in the form of lands that extend diametrically and intersect at a right angle at about the axis of the valve body and are slitted at the intersection to provide duckbill valve action. The ridges constitute the apices of mutually intersecting partially folded wall portions that are V-shaped in section, the V's spreading towards the first end where the intersecting walls join and form the valleys and the one-way action of the valve allowing fluid to move only towards the second end. The novel low profile gastrostomy tube combines a conventional dome and tubular shaft with the one-way cross-slit valve of the invention.

Abstract: An enteral nutritional product for persons infected with human immunodeficiency virus contains a soy protein hydrolysate having a degree of hydrolysis in the range of about 14 to 17 and a molecular weight partition, as determined by size exclusion chromatography, wherein 30-60% of the particles have a molecular weight in the range of 1500-5000 Daltons. The nutritional product also contains a source of intact protein. The nutritional product has a ratio, by weight, of n-6 to n-3 fatty acids of about 1.3:1 to 2.5:1. The nutritional product also contains a source of dietary fiber.